Systematic review and meta-analysis: Real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia

Bin Wei, Fanpu Ji, Yee Hui Yeo, Eiichi Ogawa, Christopher D. Stave, Shuangsuo Dang, Zongfang Li, Norihiro Furusyo, Ramsey C. Cheung, Mindie H. Nguyen

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Background Genotype 3 (GT3) is a common chronic hepatitis C (CHC) genotype in Asia. Direct-acting antiviral (DAA) regimens have high cure rates, but real-world results are limited for Asia. Aim To determine the real-world effectiveness of DAAs for patients with CHC GT3 in Asia. Methods A systematic search was performed in PubMed (including MEDLINE), Embase, and selected international meeting abstract repositories. Eligible studies were postmarketing observational studies from Asia with the primary outcome of sustained virological response 12 weeks after completion of treatment (SVR12). Results A total of 15 studies with 4230 patients yielded a pooled SVR12 of 92.7%. High heterogeneity (I2 =93.2%, P<0.0001) was noted. In subgroup analyses, patients with cirrhosis had 10.9% lower SVR12 than non-cirrhotic patients (88.6% vs 98.9%; P<0.0001) and contributed 69.5% of the heterogeneity. Prior treatment failure did not reduce the pooled SVR12 (treatment-naïve: 94.6%, 95% CI 91.3% to 96.7% vs treatment-experienced: 94.0%, 95% CI 77.5% to 98.6%; P=0.89). Twenty-four weeks of sofosbuvir+ribavirin dual therapy was the most commonly used regimen which led to similar SVR12 (OR=1.1, P=0.73) but lower adverse event rate than 12 weeks of sofosbuvir+ribavirin+pegylated interferon triple therapy. Conclusion Sofosbuvir+ribavirin for 24 weeks is the most widely used and generally well-tolerated DAA therapy in Asia. However, its effectiveness is not optimal in GT3 patients with cirrhosis.

Original languageEnglish
Article numbere000209
JournalBMJ Open Gastroenterology
Volume5
Issue number1
DOIs
Publication statusPublished - 2018

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Fingerprint Dive into the research topics of 'Systematic review and meta-analysis: Real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia'. Together they form a unique fingerprint.

  • Cite this